drugset
Drugs / NEO-811
last change Feb 2026 re-read 3 minutes ago

NEO-811

targets ARNT

Developed for
clear cell renal carcinoma
Investigated by
Neomorph, Inc

Trials 1

today NCT07300241 · Ph 1
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07300241 Dec 2025 → Jan 2027 expected clear cell renal carcinoma Neomorph, Inc Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2026-02-03 Neomorph, Inc Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma neomorph.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as NEO-811 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300241 ↗
Target ARNT “NEO-811, an ARNT molecular glue degrader” NCT07300241 ↗